Plasma Rich in Growth Factors (PRGF-Endoret) in the Regeneration of Post-Extraction Sockets

Fundación Eduardo Anitua

Status

Completed

Conditions

Post-Extraction Sockets Healing

Treatments

Biological: Plasma Rich in Growth Factors PRGF-Endoret

Procedure: Conventional closure of the lesion

Study type

Interventional

Funder types

Other

Identifiers

NCT01465399

FIBEA-01-EC/11/ALV

2019-001167-75 (EudraCT Number)

Details and patient eligibility

About

Immediately following tooth removal, a healing process begins that affects the eventual alveolar bone volume and architecture of the alveolar ridge. Satisfactory and timely healing are essential to obtain ideal functional reconstruction. Traumatic removal of a tooth, or a poor healing response, may lead to excessive bone loss delaying tooth replacement, requiring expensive and time-consuming reconstructive surgeries, or even the inability to be corrected. The Plasma Rich in Growth Factors (PRGF-Endoret) has shown its therapeutic potential effect to minimize the consequences of this aggression, promoting the regeneration of both hard and soft involved tissues.

Enrollment

60 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

subjects of both genders and ≥ 18 years old
Indication of a simple one molar extraction in the mandible.
Possibility of observation during the follow-up period.

Exclusion criteria

Unerupted third molars or with horizontal inclination.
Severe swelling prior to surgery in the areas designated for extraction.
Suffering an alteration or a serious hematologic disease.
Be currently undergoing or have received radiotherapy, chemotherapy or immunosuppressive therapy, corticosteroids and/or anticoagulants 30 days prior to inclusion
In regular treatment with NSAIDs or other anti-inflammatory drugs.
History of chronic hepatitis or cirrhosis.
Diabetes mellitus with poor metabolic control (glycosylated hemoglobin >9%)
Patients undergoing dialysis.
Presence of malignant tumors, hemangiomas or angiomas in the extraction area.
History of ischemic heart disease in the last year.
Pregnancy or planned pregnancy during the study follow-up period.
Metabolic Bone Disease.
Patients taking bisphosphonates both orally and intravenously.
In general, any inability to participate in the study.